Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Hydrocortisone autoinjector - Crossject

Next Previous
X
Search
Drug Profile

Hydrocortisone autoinjector - Crossject

Alternative Names: Needleless hydrocortisone autoinjector; ZENEO - Crossect; ZENEO® Hydrocortisone Autoinjector; ZENEO® needleless device

Latest Information Update: 19 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Crossject
  • Class Anti-inflammatories; Antiallergics; Glucocorticoids; Pregnenediones; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Adrenal insufficiency
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Adrenal insufficiency

Most Recent Events

  • 19 Apr 2024 Eton Pharmaceuticals announces intention to submit NDA to US FDA for Adrenal insufficiency in 2024
  • 31 Mar 2023 Hydrocortisone autoinjector - Crossject receives Orphan Drug status for Adrenal insufficiency in USA
  • 03 Nov 2022 Clinical trials in Adrenal insufficiency in USA (unspecified route) as of November 2022

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top